"Aniline Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the aminobenzene structure.
| Descriptor ID |
D000814
|
| MeSH Number(s) |
D02.092.146
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aniline Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aniline Compounds".
This graph shows the total number of publications written about "Aniline Compounds" by people in this website by year, and whether "Aniline Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 4 | 2 | 6 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 5 | 1 | 6 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 2 | 5 |
| 2017 | 4 | 3 | 7 |
| 2018 | 5 | 3 | 8 |
| 2019 | 4 | 8 | 12 |
| 2020 | 1 | 6 | 7 |
| 2021 | 7 | 6 | 13 |
| 2022 | 1 | 6 | 7 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aniline Compounds" by people in Profiles.
-
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135.
-
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831.
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
-
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nat Commun. 2022 09 14; 13(1):5401.
-
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 07; 36(7):1825-1833.
-
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 2022 Jun; 9(6):e434-e444.
-
Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Ann Surg Oncol. 2022 08; 29(8):4688-4689.
-
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun; 115(6):838-851.
-
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 05 20; 40(15):1671-1680.
-
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022 03 01; 97(3):322-328.